Polymerase Chain Reaction (PCR) held the largest share of the monkeypox testing market in 2025, reflecting its central role in confirmatory diagnosis where accuracy and clinical reliability are critical. PCR remains the leading technology because healthcare providers and testing centers rely on it for pathogen-specific detection, especially in settings where diagnostic certainty guides isolation decisions, treatment pathways, and public health response. Its established use within laboratory workflows and compatibility with existing molecular testing infrastructure continue to support its leadership in the monkeypox testing market.

Lateral Flow Assay (LFA) is emerging as the fastest-growing technology segment in the monkeypox testing market because it addresses the practical need for quicker and more accessible testing outside complex laboratory environments. Growth is being encouraged by rising demand for rapid screening in decentralized care settings, where ease of use and faster turnaround can improve early identification and response. Compared with PCR, LFA is gaining momentum where operational simplicity and speed matter more than full laboratory processing, making it increasingly attractive for broader deployment.

End-use Type Segment Analysis: Hospitals & Clinics (Largest Segment) vs Diagnostic Laboratories (Fastest-Growing Segment)

In 2025, Hospitals & Clinics accounted for the largest share of the monkeypox testing market, backed by their position as the first point of care for patients presenting with suspected symptoms. This segment leads because testing decisions are often initiated in clinical settings where patient evaluation, sample collection, and immediate case management occur together. Hospitals and clinics also remain central to the monkeypox testing market due to their direct role in managing infection control protocols and coordinating timely diagnosis within routine care delivery.

Diagnostic Laboratories represent the fastest-growing end-use segment in the monkeypox testing market as testing volumes increasingly move toward facilities built for scalable processing and standardized diagnostic workflows. Their growth is tied to the need for higher throughput, stronger technical specialization, and more efficient handling of confirmatory testing as demand becomes more structured. Relative to hospitals and clinics, diagnostic laboratories are gaining momentum because they are better positioned to expand dedicated testing capacity while maintaining consistency across larger sample loads.